RUA Life Sciences Plc

As of September 30, 2024, RUA Life Sciences Plc carries a market capitalization of 837.81M, placing it among publicly traded companies globally. Its enterprise value stands at 589.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

RUA Life Sciences Plc's next confirmed earnings release is scheduled for July 19, 2027.

As of September 30, 2024, RUA Life Sciences Plc has 62.06M shares outstanding.

These figures are as of September 30, 2024.

As of September 30, 2024, RUA Life Sciences Plc maintains a current ratio of 6.47, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, RUA Life Sciences Plc's stock has gained approximately 144.44% over the past 52 weeks. The 50-day moving average sits at 27.83, while the 200-day moving average is 20.42.

As of September 30, 2024, RUA Life Sciences Plc holds 377.90M in cash and equivalents against 117.60M in total debt, resulting in a net debt position of -346.20M. Total book value stands at 786.30M, with working capital of 499.50M providing operational flexibility.

RUA Life Sciences Plc's most recent stock split took place on December 14, 2020 with a 185:186 split ratio.